Saida Nawal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saida Nawal has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Eftekhar Alam
Department of Electrical and Electronic Engineering EEE and Computer Science and Engineering (CSE), International Islamic University Chittagong, Chittagong 4318, Bangladesh
1 shared publication - Farzana Tasnim
International Islamic University Chittagong
1 shared publication - Karl Andersson
Cybersecurity Laboratory, Luleå University of Technology, SE-931 87 Skellefteå, Sweden
1 shared publication - Mohammad Shahadat Hossain
University of Chittagong
1 shared publication - Samia Afreen Dolon
Department of Computer Science and Engineering, International Islamic University Chittagong, Chittagong 4318, Bangladesh
1 shared publication - Sanjida Sharmin
Department of Computer Science and Engineering, International Islamic University Chittagong, Chittagong 4318, Bangladesh
1 shared publication
Latest Publications
- Open Access
- 8 November 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (22) , 2833
A Hybrid MCDM and Machine Learning Framework for Thalassemia Risk Assessment in Pregnant Women
Background: Thalassemia has been recognized as a critical public health issue in Bangladesh, especially among pregnant women, due to its hereditary nature and the lack of early screening infrastructure. Early identification of at-risk individuals is essential to prevent the transmission of this genetic disorder to future generations and to reduce the burden on an already strained healthcare system. Methods: In this study, an innovative framework for thalassemia risk assessment has been developed by integrating Multi-Criteria Decision-Making (MCDM) methods—specifically AHP-TOPSIS—with machine learning algorithms including Random Forest, XGBoost, and CatBoost. Explainable Artificial Intelligence (XAI) techniques such as SHAP and LIME have also been incorporated to improve model transparency and trustworthiness. Real-world clinical and demographic data, consisting of 16 features and 1200 samples, have been collected through a structured survey and processed using rigorous feature selection and ranking methods. Risk stratification has been performed to classify patients into high, medium, and low categories, enabling targeted intervention. Results: Among all models, the XGBoost classifier trained on AHP–TOPSIS–prioritized features achieved a consistent accuracy of 99.28% under stratified 20-fold cross-validation, demonstrating robust diagnostic classification performance. The model predominantly captures hematologic patterns characteristic of thalassemia manifestations, functioning as an assistive diagnostic framework rather than a causal risk predictor. The explainability of predictions, ensured through comprehensive visual and statistical analyses, further enhances the model’s clinical transparency and reliability. Conclusions: The proposed MCDM–machine learning framework demonstrates strong potential for improving thalassemia risk assessment, enabling early detection and informed decision-making in maternal healthcare. The proposed framework should be regarded as a preliminary proof-of-concept system that demonstrates the feasibility of integrating Multi-Criteria Decision-Making (AHP–TOPSIS) with advanced machine learning and explainable-AI techniques for thalassemia assessment. Although the model achieved strong diagnostic performance under nested cross-validation, additional external validation and inclusion of causal predictors are required before clinical deployment.
- 8 November 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (22) , 2833
Open AccessA Hybrid MCDM and Machine Learning Framework for Thalassemia Risk Assessment in Pregnant Women
Background: Thalassemia has been recognized as a critical public health issue in Bangladesh, especially among pregnant women, due to its hereditary nature and the lack of early screening infrastructure. Early identification of at-risk individuals is essential to prevent the transmission of this genetic disorder to future generations and to reduce the burden on an already strained healthcare system. Methods: In this study, an innovative framework for thalassemia risk assessment has been developed by integrating Multi-Criteria Decision-Making (MCDM) methods—specifically AHP-TOPSIS—with machine learning algorithms including Random Forest, XGBoost, and CatBoost. Explainable Artificial Intelligence (XAI) techniques such as SHAP and LIME have also been incorporated to improve model transparency and trustworthiness. Real-world clinical and demographic data, consisting of 16 features and 1200 samples, have been collected through a structured survey and processed using rigorous feature selection and ranking methods. Risk stratification has been performed to classify patients into high, medium, and low categories, enabling targeted intervention. Results: Among all models, the XGBoost classifier trained on AHP–TOPSIS–prioritized features achieved a consistent accuracy of 99.28% under stratified 20-fold cross-validation, demonstrating robust diagnostic classification performance. The model predominantly captures hematologic patterns characteristic of thalassemia manifestations, functioning as an assistive diagnostic framework rather than a causal risk predictor. The explainability of predictions, ensured through comprehensive visual and statistical analyses, further enhances the model’s clinical transparency and reliability. Conclusions: The proposed MCDM–machine learning framework demonstrates strong potential for improving thalassemia risk assessment, enabling early detection and informed decision-making in maternal healthcare. The proposed framework should be regarded as a preliminary proof-of-concept system that demonstrates the feasibility of integrating Multi-Criteria Decision-Making (AHP–TOPSIS) with advanced machine learning and explainable-AI techniques for thalassemia assessment. Although the model achieved strong diagnostic performance under nested cross-validation, additional external validation and inclusion of causal predictors are required before clinical deployment.